Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06475105

Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes

Based on ADVOR trial, the potential of adding acetazolamide in increasing the success of decongestion, the amount of natriuresis and diuresis. However, the use of intravenous acetazolamide may not be possible in Indonesia, where the intravenous formulation is not available. This clinical research study is being conducted in single hospitals in Indonesia. We aim to learn if Oral Acetazolamide in addition to Furosemide intravenous works to treat congestion in Acute Decompensated Heart Failure, besides evaluating the total urinary output, change of NT pro BNP level, and safety profile of oral Acetazolamide.

The hypothesis of this study is oral acetazolamide works well to achieve successful decongestion.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Decompensated Heart Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Cardiology and Vascular Medicine, Universitas Diponegoro, Kariadi Central General Hospital, Semarang, Central Java, Indonesia

Loading trial locations.

About this study

This is a randomized, double blind study with 2 treatment groups. Participants diagnosed with ADHF who meet the inclusion criteria and no exclusion criteria are given an explanation regarding the research and additional therapy that will be given, then informed consent is requested. Participants will be randomized to one of the two treatment groups by chance. Patients randomized to the first group will receive intravenous furosemide and oral acetazolamide. Patients randomized to the other treatment group will receive a combination of iv furosemide and placebo. It is expected that the patients of the treatment group with the combination therapy will have a faster reduction of their fluid overload. In consequence the treatment duration and total dose of diuretics administered will be shorter.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Agree to be included in the research by signing informed consent
  • Patients with a clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload with a congestion score ≥2 (ADVOR Score) (e.g. edema (score 2 or more), ascites confirmed by physical examination or ultrasonography or pleural effusion confirmed by chest x-ray or echocardiography).
  • Patients on routine oral loop diuretic therapy with a dose of ≥40 mg furosemide for ≥1 month
  • Plasma NT-proBNP levels that increase ≥300 pg/mL or the applicable cut-off according to the age range at the time of examination in the ER.

Exclusion criteria

  • Subjects with acute coronary syndrome
  • History of congenital heart disease requiring surgical correction.
  • Subjects in cardiogenic shock.
  • Estimated glomerular filtration rate <20 mL/min/1.73m² at the time of examination.
  • Use of renal replacement therapy or ultrafiltration at any time before the study was included.
  • Treatment with acetazolamide within 1 month before randomization.
  • Exposure to nephrotoxic agents (i.e. contrast dye) is anticipated within the next 3 days
  • Subjects who are pregnant or breastfeeding.
  • Subjects with urinary incontinence who are unwilling to use a bladder catheter.

Treatment and study plan

Oral Acetazolamide

Drug

Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days

Other names: Glauseta

Placebo

Drug

Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days

Primary outcomes

  1. Successful Decongestion

    Time frame: within 3 days

    Conditions without volume overload, no signs of excess volume within 3 days of treatment. Congestion was assessed using the volume assessment score (also called congestion score) from the ADVOR trial. The absence of fluid volume excess was defined as no more than mild edema, no residual pleural effusion, and no residual ascites. Total score ≤1 indicates that decongestion has been achieved, score >1 is considered to indicate persistent fluid volume excess (decongestion not achieved).

Secondary outcomes

  1. NT pro BNP

    Time frame: within 3 days

    the effect of adding combination oral acetazolamide on NT pro BNP levels in ADHF participants who received iv furosemide

  2. Renal Function

    Time frame: From date of randomization until the date of first documented worsening renal function (increased of creatinine serum level >50% of baseline creatinine) or date of death from any cause, evaluation every 48 hours or whichever came first, up to 90 days

    Kidney function is measured based on estimated GFR (eGFR) according to the CKD-EPI formula which is shown in units of mL/min/1.73 m2 taken on day 0, day 2, and day 4, every 48 hours during hospitalization (after receiving treatment).

  3. Urinary Output

    Time frame: From date of randomization until participants discharge from hospital up to 7 days post discharge.

    the amount of urine for 24 hours is measured from the time the patient arrives at the emergency room, a urinary catheter tube is installed, measured every 24 hours during hospital treatment.

  4. Length of Stay

    Time frame: From date of randomization until the date of first documented progression and discharge from hospital or date of death from any cause, whichever came first, assessed up to 30 days.

    Defined as the duration of the patient receiving treatment in hospital from the time admitted to the ER until the patient was discharged/discharged from the hospital, obtained as the date of discharge from the hospital minus the sampling date +1.

Study contacts

Contact information is provided by the study sponsor or research team.

Inne P Farissa, MD

CONTACT

[email protected]

024-8413476 ext. 6282

Tahari B Prakoso, MD

CONTACT

[email protected]

024-8413476 ext. 6282

Sponsors and collaborators

Lead sponsor

Universitas Diponegoro

Other

Registry information

Official study title

Effects of Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure

Acronym: COAF-HF

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jun 26, 2024
Registry last updated
Oct 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.